FOXP3 and neoplasm: Recent studies have demonstrated that increased proportion of tumor-infiltrating FoxP3+ Tregs predict a poor prognosis of patients with cancer, including breast [5], ovarian [6], hepatocellular [7] and gastric carcinomas [8].